OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis	244
The preclinical discovery and development of zanubrutinib for the treatment of chronic lymphocytic leukemia	152
Training recurrent neural networks as generative neural networks for molecular structures: how does it impact drug discovery?	116
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	77
An insight into artificial intelligence in drug discovery: an interview with Professor Gisbert Schneider	73
Advances in the discovery of drugs that treat pulmonary arterial hypertension	65
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	65
The discovery and development of novel treatment strategies for filoviruses	64
The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies	63
The latest advances in high content screening in microfluidic devices	58
Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease	55
Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities	48
Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies	48
Advances in ion channel high throughput screening: where are we in 2023?	48
Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure	46
What is an ideal antibiotic and what does this mean for future drug discovery and design?	45
Discovery of RNA-targeted small molecules through the merging of experimental and computational technologies	42
What is the future of click chemistry in drug discovery and development?	40
Lessons learned from phenotypic drug discovery efforts	40
The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics	36
Advances in cryo-electron microscopy (cryoEM) for structure-based drug discovery	35
Future prospects of accelerating neuroactive drug discovery with high-throughput behavioral phenotyping	35
Inhibitors and PROTACs of CDK2: challenges and opportunities	34
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)	34
Overcoming multidrug resistance through targeting ABC transporters: lessons for drug discovery	33

Fluorescent quantum dots enable SARS-CoV-2 antiviral drug discovery and development	33
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence	31
Developing our knowledge of the quinolone scaffold and its value to anticancer drug design	31
Recent advances in measurement of metabolic clearance, metabolite profile and reaction phenotyping of low clearance compounds	30
Biocatalysis for the asymmetric synthesis of Active Pharmaceutical Ingredients (APIs): this time is for real	29